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Background: A recently developed 10-valent pneumococcal non-typeable H influenzae protein D-conjugate
vaccine (PHiD-CV) is expected to afford protection against more than two thirds of isolates causing IPD in children
in Latin America, and also against acute otitis media caused by both Spn and NTHi. The objective of this study is to
assess the cost-effectiveness of PHiD-CV in comparison to non-vaccination in children under 10 years of age in
Argentina, Brazil, Chile, Colombia, Mexico and Peru.
Methods: We used a static, deterministic, compartmental simulation model. The dosing regimen considered
included three vaccine doses (at 2 months, 4 months and 6 months) and a booster dose (at 13 months) (3 + 1
schedule). Model outcomes included number of cases prevented, deaths averted, quality-adjusted life-years (QALYs)
gained and costs. Discount for costs and benefits of long term sequelae was done at 3.5%, and currency reported
in 2008-2009 U$S varying between countries.
Results: The largest effect in case prevention was observed in pneumococcal meningitis (from 27% in Peru to 47%
in Colombia), neurologic sequelae after meningitis (from 38% in Peru to 65% in Brazil) and bacteremia (from 42% in
Argentina to 49% in Colombia). The proportion of predicted deaths averted annually ranged from 18% in Peru to
33% in Brazil. Overall, the health benefits achieved with PHiD-CV vaccination resulted in a lower QALY loss (from
15% lower in Peru to 26% in Brazil). At a cost of USD 20 per vaccine dose, vaccination was cost-effective in all
countries, from being cost saving in Chile to a maximum Incremental Cost-effectiveness Ratio of 7,088 US$ Dollars
per QALY gained. Results were robust in the sensitivity analysis, and scenarios with indirect costs affected results
more than those with herd immunity.
Conclusions: The incorporation of the 10-valent pneumococcal conjugate vaccine into routine infant immunization
programs in Latin American countries could be a cost-effective strategy to improve infant population health in the
region.Background
Acute respiratory infections are the leading cause of
death in children under 5 years of age worldwide, and
around 2 million infants and young children die annually
due to pneumonia [1]. The most common causative
agents of bacterial pneumonia in children are Streptococ-
cus pneumoniae (Spn) and Haemophilus influenzae; both* Correspondence: garciamarti@iecs.org.ar
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reproduction in any medium, provided the orbacteria are also responsible for many cases of sepsis,
meningitis and acute otitis media (AOM) [2,3].
In Latin America and the Caribbean, Spn is estimated
to account for 18,000 pneumococcal deaths, 327,000
cases of pneumonia, 4,000 meningitis and 1,229 sepsis
each year in children aged under five years [2]. In
addition, around 10.5 million episodes of AOM occur in
children under 5 years of age per annual birth cohort
[2,4], 30% of which are caused by Spn [5] and 18% per
H. influenza [5]. The overall burden of pneumococcal
disease in the pediatric population in the region is esti-
mated at 600,000 Disability Adjusted Life Years [2].d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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diseases vary across the countries [3].
New conjugate vaccines have been developed that are
immunogenic in children younger than 2 years of age. A
recently developed 10-valent pneumococcal non-typable
H influenzae protein D-conjugate vaccine (PHiD-CV) of-
fers a broad spectrum of coverage against Spn strains in-
cluding serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and
23F. Some of these serotypes have a high prevalence in
Latin America and the Caribbean. Serotype 14 accounts
for 21.1% of all invasive isolates in the region (29.1% in
children under 6 years old) [6]. According to this profile,
PHiD-CV is expected to afford protection against 76.5%
of isolates causing invasive pneumococcal disease (IPD) in
children aged < 5 years in Latin America [6]. Moreover
PHiD-CV offers additional benefits since 8 of 10 vaccine
strains are conjugated to protein D from non-typable Hae-
mophilus influenzae (NTHi) and there is evidence that the
vaccine induces additional protection against acute otitis
media caused by both Spn and NTHi [7].
The introduction of pneumococcal vaccination in re-
gional routine infant immunization programs may have a
highly significant impact on health budgets, particularly in
developing countries where health care resources are lim-
ited. However, several other factors constrain the incorp-
oration of new vaccines into local immunization programs
[8]. The availability of accurate and reliable data therefore
becomes crucial to foster decision-making based on cost
effectiveness criteria. Even though initial healthcare costs
may be high, delayed vaccine introduction may result in
thousands of immuno-preventable disease and deaths and
many years of healthy life lost. Cost- effectiveness analysis
is a useful tool for assessing issues of efficiency in health
care resource allocation. By comparing economic evalu-
ation results with country-specific willingness to pay
thresholds, decision makers can better evaluate cost-
effectiveness of health interventions at a national level.
The aim of this study was to assess the cost-
effectiveness of PHiD-CV in comparison to no vaccination
in children under 10 years of age in six Latin American
countries: Argentina, Brazil, Chile, Colombia, Mexico and
Peru. In these countries, pharmacoeconomic data were re-
quired formally or informally to facilitate the decision
making process of vaccine introduction and this paper
was generated to address this need.
Material and methods
Model
We used a previously described static, deterministic deci-
sion tree simulation model [9]. The model was adapted to
estimate the health burden and costs related to pneumo-
coccal disease in the population under 10 years old and to
determine cost-effectiveness of PHiD-CV, during one year
and assuming steady state. This steady state reflects theoutcomes associated with vaccination of a cohort of new-
borns in the current year, as well as the carry-over effects
of vaccination from previous years of older cohorts. Net
present value of all future costs and benefits (during each
person’s expected lifetime) is imputed to the steady-state
population during the current year. The model used a de-
terministic framework to assess the impact of vaccination
on the population by calculating the reduction in the inci-
dence of disease associated with Spn and NTHi and esti-
mated both vaccination program costs as well as total costs
averted with vaccination. Four different main health out-
comes were included in the model: all-cause pneumonia
(hospitalized and ambulatory), all-cause AOM (including
tube insertion), pneumococcal meningitis and pneumococ-
cal bacteremia. Only cases of hospitalized IPD, which en-
compasses meningitis and bacteremia, were considered.
Chronic hearing sequelae after AOM and chronic hearing
and neurologic sequelae after meningitis were also
assessed. Model framework and health events addressed
were previously described in detail [9].
The model included two different strategies: no vac-
cination and vaccination with PHiD-CV. We assumed
vaccination coverage reached 95% of the target popula-
tion. This percentage was considered adequate to esti-
mate current national immunization coverage levels in
most countries included in the analysis, as its value is
similar to actual coverage rates [10]. The dosing regimen
considered consists in three vaccine doses (at 2 months,
4 months and 6 months) and a booster dose (at
13 months) (3 + 1 schedule). The vaccine is considered
to provide some level of protection from the first dose
through the assumed duration of efficacy [9]. For the
main analysis only direct effects of vaccination in chil-
dren under the age of 10 years old were considered, as-
suming no protection against pneumococcal disease in
older children and adults. As the herd immunity varies
across countries with different effects, a secondary ana-
lysis [11-14] estimated indirect effects of vaccination on
the population (herd immunity and serotype replace-
ment). Principal inputs to the model included epidemio-
logical information on disease incidence, disutility and
costs associated with disease events, vaccine effective-
ness and costs of vaccination. Model outcomes included
number of cases prevented, deaths averted, quality-
adjusted life- years (QALYs) gained and costs.
Epidemiological data
Local epidemiological data were incorporated for each coun-
try to reflect country-specific context. Data were retrieved
from different sources. First, we conducted two systematic
reviews (bibliographic databases MEDLINE, EMBASE, LI-
LACS, regional scientific meeting abstracts, national statis-
tics and statistics from international organizations) in order
to determine incidence, etiology and use of health resources
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Latin America and the Caribbean region [5,15]. An add-
itional literature review was conducted to obtain informa-
tion not contained in prior systematic reviews for IPD.
Local key opinion leaders in pediatrics infectious diseases
were asked to provide bibliographic sources when available.
Second, for data not found in published literature, we
sought expert consensus using country level modified Del-
phi method [16]. Two expert panels were convened in each
country, one for ambulatory and the other for hospitalized
health events. Each panel comprised 6 to 8 local pediatric-
oriented experts who participated in two rounds of ques-
tions by mail. The selection of the physicians that accepted
to participate were a convenience sample representative of
the different health system subsector.
After the model was completed, epidemiological input
parameters and burden of disease estimations obtained for
each country were validated via review with local experts.
Demographic estimates for 2008 grouped by age and gen-
der were used for each country to convert rates into abso-
lute numbers as required by the model [17-21]. In the
case of Peru and Argentina, demographic estimates used
corresponded to 2007 and 2006 respectively [22,23].
Baseline disease estimations
Burden of disease for the different health events was es-
timated taking into account the following inputs that
were included in the model: hospitalization rates, case
fatality ratios (CFRs), hospitalization ratios, and the inci-
dence of ambulatory cases.
For all-cause pneumonia, hospitalization rates and CFRs
for Brazil, Chile and Mexico were obtained from national
health statistics: Sistema Único de Saúde (SUS) in Brazil
[24], National Health System in Chile (División de
Planificación Sanitaria. Departamento de Estadísticas e
Información de Salud. Ministerio de Salud de Chile, per-
sonal communication. April, 2009), and from the social se-
curity Instituto Mexicano del Seguro Social in Mexico
(IMSS) [25]. As hospitalization rates were not available for
Colombia, Peru and Argentina, estimates of all cause
pneumonia were derived from mortality rates using Equa-
tion 1. In the case of Colombia and Peru mean CFR for
Brazil, Chile and Mexico were applied, and it was obtained
from Delphi Panel in the case of Argentina. In all coun-
tries we assumed that all deaths occurred during
hospitalization, except for Peru, where only 46% of deaths





Ambulatory pneumonia cases were estimated in all coun-
tries from hospitalization rates based on the proportion ofpneumonia requiring hospitalization (hospitalization ratio)




– incidenceof hospitalized pneumonias
ð2Þ
The number of ambulatory cases of all-cause AOM for
Brazil and Mexico was derived from local studies [27,28].
Incidence rate of AOM in children under 4 years-old from
Chile was obtained from a local study [29], assuming a dec-
rement in incidence after that age similar to that reported
in Brazil. Incidence rate for Colombia, Peru and Argentina
was assumed to be the mean rate of data from Brazil, Chile
and Mexico. In addition, for all countries the number of
myringotomy procedures due to all-cause AOM and the
percentage of cases of AOM-related hearing sequelae were
calculated by multiplying AOM incidence by the corre-
sponding percentages provided by the Delphi panels.
For IPD, only hospitalized cases were included. The inci-
dence of pneumococcal meningitis and pneumococcal
bacteremia were estimated separately based on the inci-
dence of all-cause IPD and the percentage of cases caused
by Spn using Equation 3. Incidence of all-cause IPD for
Brazil, Chile and Mexico were obtained from same local
data sources mentioned for pneumonia. Values were de-
rived from mortality rates using Equation 1 for Colombia,
Peru and Argentina. Percentage of IPD cases attributable to
pneumococci, CFRs for IPD and percentage of meningitis-
related hearing and neurologic sequelae were derived from
Delphi panels in all countries.
Incidenceof Spn invasivedisease IDð Þ
¼ Incidenceof IDx %of IDassociate toSpn ð3Þ
Hospitalization rates for the different diseases were ex-
trapolated from national statistics, after adjusting for es-
timated population coverage. Data were obtained from
the IMSS database for Mexico [19] assuming 42.2% of
the population had access to social security coverage
[25]. Data were collected from DATASUS database for
Brazil [30], assuming 87% coverage, (similar to mortality
data [31]). Data for Chile were provided by the Depart-
ment of Health Statistics and Information (DEIS) (Div-
isión de Planificación Sanitaria 2009 Departamento de
Estadísticas e Información de Salud. Ministerio de Salud
de Chile. Personal Communication) assuming 94%
coverage according to the World Health Organization’s
Statistical Information System (WHOSIS) [32].
Hospitalization rates for pneumonia, meningitis and
bacteremia for Colombia were extrapolated from mortality
rates obtained from the National Administrative Depart-
ment of Statistics (DANE) adjusted for estimated coverage
of mortality collected from WHOSIS [18,32] assuming
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were extrapolated from mortality rates provided by the
General Office of Statistics and Information (OGEI) [33]
assuming 68% coverage according to WHOSIS [32]. In the
case of Argentina, mortality rates were obtained from
Health Statistics and Information Department (DEIS) [22]
assuming 94% coverage according to WHOSIS [32].
Tables 1 and 2 summarize the epidemiological input data














0-1 years 1,323.80 3.5 4,026.60 0.8 6,526.20
1-4 years 257.4 1.5 1,562.80 0.2 1,563.20
5-9 years 109.9 1 362 0.2 388.6
All-cause pneumonia
(ambulatory) §
0-1 years 441.3 - 3,643.10 - 15,227.8
1-4 years 922.4 - 4,748.40 - 7,555.30
5-9 years 1,721.90 - 3,775.10 - 7,384.30
All-cause AOM ll
0-1 years 8,943.50 - 6,050.90 - 16,260.2
1-4 years 7,690.50 - 7,563.60 - 10,988.6
5-9 years 4,626.90 - 2,915.30 - 2,882.60
Pneumococcal
meningitis¶
0-1 years 19.4 16.1 22.5 40 39.4
1-4 years 0.74 16.1 4.6 25 5.4
5-9 years 0.12 16.1 2.3 10 3.1
Pneumococcal
bacteraemia/sepsis**
0-1 years 54.2 5.5 171.2 22.5 61.5
1-4 years 9.16 4 8.9 11.3 6.8
5-9 years 4.33 1 2 6.5 1.3
* per 100,000 people.
†CFR = Case Fatality Ratio.
‡Pneumonia hospitalization rate and CFR for Brazil and Chile were obtained from n
Health System in Chile (División de Planificación Sanitaria. Departamento de Estadís
communication. April, 2009); The same figures for Mexico were obtained from the s
Colombia, Peru, and Argentina were derived from mortality rates applying mean CF
occurred during hospitalization, except Peru, where only 46% of deaths were assum
§Cases of ambulatory pneumonia were estimated in all countries from hospitalizati
provided by Delphi panels.
ll Number of cases of AOM for Brazil and Mexico were derived from local studies [2
local study for Chile [29]., assuming the same age decrement in the incidence rate
be the mean rate between Brazil, Chile and Mexico.
¶ ** The incidence of pneumococcal meningitis and of pneumococcal bacteremia w
percentage of cases caused by Spn. Incidence of all-cause IPD for Brazil, Chile and M
all-cause IPD for Colombia, Peru and Argentina were derived from mortality rates. P
Delphi panels for all countries. Delphi panels in Brazil were provided with additionaVaccine effectiveness
Since evidence of vaccine effectiveness against pneumo-
nia is not available for PHiD-CV at the moment of the
analysis, it was estimated using data from the Northern
California Kaiser Permanente trial for the 7-valent con-
jugate vaccine (PCV-7) which contains seven shared se-
rotypes [34] and assumed to be the same for all
participating countries (Table 3). Vaccine effectiveness















0.5 2,715.30 3.4 639.8 8.9 2,130.50 7.4
0.1 1,147.76 0.8 273.31 2 1,034 1.7
0 273.3 0.6 31.2 1.6 262.6 1.4
0 - 301.7 - 185.8 - 236.7 -
- 1,265.48 - 956.6 - 646.24 -
- 2,211 - 281 - 1,050.40 -
0 - 8,943.50 - 4,519.40 - 8,943.50 -
0 - 7,690.55 - 4,519.40 - 7,690.50 -
- 4,626.90 - 1,921.90 - 4,626.90 -
12.3 28.4 17.5 5.76 40 5.1 20
10 5.35 13.75 0.61 18.5 1.62 7.5
10 1.4 4 0.07 5.5 4.9 2
7.5 61.7 12.5 101.8 30 54.2 20
2 9.3 7.5 8.94 17.5 8.52 12.5
2 2.1 3.5 0.42 5 2.5 2
ational health statistics: Sistema Único de Saúde (SUS) in Brazil [24], National
ticas e Información de Salud. Ministerio de Salud de Chile, personal
ocial security Instituto Mexicano del Seguro Social (IMSS) [25]. Estimates for
R for Brazil, Chile and Mexico. In all countries we assumed that all deaths
ed to occur in the hospital [26].
on rates based on the proportion of pneumonia requiring hospitalization
7,28]. Incidence rate for children under 4 years-old was obtained from other
as described for Brazil Incidence rates for Colombia and Peru were assumed to
ere estimated separately based on the incidence of all-cause IPD and the
exico were obtained from the same sources as pneumonia. Incidence of
ercentage of IPD cases attributable to Spn and CFRs for IPD were derived from
l information from local studies.
Table 2 Epidemiological input data: complications and chronic sequelae1



























0-1 years 0.02% 10.0% - 0.05% 10% - 0.03% 10% - 0.07% 10% - 0.02% 12.50% - 0.01% 13.50% -
2-4 years 0.02% 4.00% - 0.02% 4% - 0.03% 4.50% - 0.07% 7.50% - 0.05% 7.50% - 0.04% 6.24% -
5-9 years 0.01% 2.00% - 0.01% 1% - 0.02% 2.50% - 0.01% 2% - 0.03% 3% - 0.01% 1.50% -
Pneumococcal
meningitis
0-1 years - 5.88% 17.63% - 10% 40% - 25% 25% - 56.30% 18.80% - 12% 28% - 6% 24%
2-4 years - 2.34% 14.53% - 10% 40% - 11.10% 20.10% - 25.50% 23.25% - 4.25% 17% - 4.30% 23.25%
5-10 years - 0.70% 9.30% - 10% 36% - 5% 15% - 58.20% 15.28% - 1.90% 10.60% - 0.50% 9.50%
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ical pneumonia [34] for PCV-7, and used as a proxy for
non hospitalized pneumonia. PHiD-CV was assumed to
be slightly more effective (25% effectiveness instead of
20.5% as shown in NCKP trial [34]) than PCV-7 against
radiologically confirmed pneumonia (used as a proxy for
hospitalized pneumonia) based on expert opinion given
that the additional serotypes covered by this vaccine are
frequent agents of severe pneumonia.
In the case of AOM, vaccine effectiveness was calculated
based on vaccine efficacy and Spn and NTHi prevalence.
The model used the distribution of Spn serotypes and
NTHi pathogens to calculate the percentage of cases
avoided. Because vaccine effectiveness against AOM was
not available by serotype, estimation was based on efficacy
against episodes due to pneumococcal types covered by
the vaccine, against episodes due to non-vaccine serotypes
and against AOM episodes caused by NTHi (Table 3). Ef-
ficacy data for PHiD-CV were taken from an 11-valent
version of PHiD-CV study by Prymula et al. [7], showing a
58% and 36% efficacy to reduce vaccine covered pneumo-
coccal serotypes AOM and NTHi episodes respectively.
Although not observed in Prymula et al. study, an increase
in the frequency of AOM due to non-covered pneumo-
coccal serotypes (type replacement) was assumed for
PHID-CV, as described for PCV-7 (33% increase) based
on Eskola et al. [35] and expert recommendation. In
addition, cross protection against AOM due to pneumo-
coccal serotype 6A of 76% was assumed [35,36]. Finally,
maximum vaccine effectiveness was estimated as shown in
Equation 4 considering the efficacy and prevalence for the
three different groups of AOM pathogens. Local distribu-
tion of pneumococcal serotypes and NTHi were obtained
from a meta-analysis previously cited [5,15]. In Argentina,
Chile and Mexico specific sources identified by systematic
review were also consulted [37-39].
Effectiveness ¼ %Spn ESpn þ%SpnNC
 ESpnNC þ%NTHi ENTHi ð4Þ
Finally, vaccine effectiveness for reduction in myringot-
omy procedures was estimated by using data taken fromTable 3 Maximum vaccine effectiveness
Argentina Brazil
All-cause pneumonia (hospitalized) 25% 25%
All-cause pneumonia (ambulatory) 4.30% 4.30%
All-cause AOM* 29.90% 18%
Myringotomy procedure 85.80% 51.72%
IPD† 76.29% 77.82%
*AOM Acute otitis media.
†IPD Invasive pneumococcal disease.Black et al. [40], showing that PCV-7 was about 2.87 times
more effective in preventing myringotomies than AOM
episodes. PHiD-CV was assumed to have the same relative
effect than PCV-7 in reduction in myringotomies.
In order to estimate vaccine effectiveness against IPD,
vaccine efficacy was adjusted for differences in pneumo-
coccal serotype distribution. Vaccine effectiveness against
IPD was based on serotype-specific efficacy from a case–
control study reported by Whitney et al. [36] for PCV-7.
Equal serotype-specific efficacy was assumed for PHiD-
CV as described for the shared vaccine serotypes on
PCV7. The average vaccine efficacy observed against
PCV-7 vaccine serotypes (94.7%) was used for the add-
itional serotypes covered by PHiD-CV, based on expert
recommendation. Vaccine efficacy for IPD was adjusted
using country-specific serotype distribution provided by
PAHO’s Network System for the Surveillance of Bacter-
ial Agents responsible for Pneumonia and Meningitis
(SIREVA) [41,42] (Table 3). In addition, cross protection
against 6A and 19A serotypes was assumed for IPD,
based on cross protection demonstrated in PCV-7 stud-
ies [35,36,43] a review on cross protection to 19A [44]
and cross reaction demonstrated in PHiD-CV immuno-
genicity studies [45].
Final vaccine effectiveness estimates were used to cal-
culate the maximum reduction in disease among the
vaccinated population (Table 3). These estimates repre-
sent the maximum effectiveness achieved by vaccination.
The model assumes that there is a period of increasing
efficacy, where the vaccine confers partial protection
until the booster dose is administered. Full protective ef-
ficacy from the vaccine (maximum published efficacies)
is assumed to begin after the booster dose. Because im-
munity may wane with time, the model assumes that the
full protection provided after booster dose persists up to
3 years of age. Thereafter, full protection from the vac-
cine is assumed to decline lineally by 28% each year, up
to the age of 10 years, when any direct protection is as-
sumed to disappear, as previously detailed [9].
No herd immunity was considered in the base case sce-
nario. There is no clear pattern in herd effect observed
across countries following the introduction of PCV7 forChile Colombia Mexico Peru
PHiD-CV
25% 25% 25% 25%
4.30% 4.30% 4.30% 4.30%
24.60% 18.20% 20.70% 18.20%
70.53% 52.13% 59.55% 52.13%
71.60% 80.41% 67.73% 69.99%
Martí et al. Cost Effectiveness and Resource Allocation 2013, 11:21 Page 7 of 17
http://www.resource-allocation.com/content/11/1/21the reduction of invasive disease [11,12,14]. To date, the
magnitude of the net indirect effect in the US has not been
clearly replicated in other settings with high PCV7 use.
Due to the lack of a clear herd effect process and the fact
that the net indirect effect result may be a consequence of
many different factors (e.g. vaccine and non-vaccine sero-
type coverage, duration of national immunization, epi-
demiology, vaccine schedule, immunization coverage,
force of infection, contact matrix and demography), no
herd immunity was considered in the base case scenario
to produce a conservative analysis. In the scenarios where
herd immunity was evaluated, we used a fixed herd effect
value. In this scenario only herd protection against inva-
sive disease was modeled. A net reduction of 15.4% was
assumed in children under five and a net reduction of 29%
was assumed from five years old until death [46].
Costs
Both direct and indirect costs were included in the model.
Direct costs comprised: vaccine cost and cost of treatment
for pneumococcal diseases and sequelae, and are reported
in 2008 US Dollars (US$) for Brazil, Chile, Colombia,
México and 2009 US$ for Argentina and Peru. The differ-
ences in cost years in some of the countries are due to the
date of availability of costs when they were obtained and
also we tried to match the epidemiological data years.
They were not inflationed or deflated to a common coun-
try date due to the potential error that it can be intro-
duced with this methodology because of particular
characteristics of regional economies [47]. Given that costs
for acute conditions are incurred in the same year as that
of the analysis, no discount was applied to them. However,
an annual 3.5% discount was applied to future costs asso-
ciated to sequelae or chronic consequences.
We estimated country specific costs for pneumococcal
disease and for sequelae. Micro-costing method was used
which permits use of detailed resource categories as well as
utilization rates and unit prices for each health event. In all
countries utilization rates for each event were estimated by
Delphi method. Unit costs reported by SOAT [48] and by
IMSS [49] were selected for resources used for health
events and hearing sequelae (hearing aids and cochlear im-
plants) for Colombia and Mexico, respectively. In Chile
costs for resources were obtained from CIGES 2008
(Centro de Capacitación, Investigación y Gestión para la
Salud Basada en Evidencias (2008) Ministerio de Salud de
Chile) and (Temuco: Universidad de La Frontera. Unpub-
lished data) and unit costs for hearing sequelae were
obtained from Garantías Explícitas en Salud [50]. In Brazil,
unit costs for health event resources were provided by SIA/
SUS and DATASUS [24,51-53] and for hearing sequelae by
DATASUS. However, for events requiring hospitalizations
in Brazil, final costs were estimated by macro-costing
method (DATASUS source) [24]. In Peru, costs wereestimated as an average from three different sources,
representing public [54], social security (from Sub
Gerencia de Costos del Seguro Social de Salud, personal
communication) and private sectors (from Complejo
Hospitalario San Pablo, personal communication). The
same approach was used for Argentina, taking into ac-
count the proportion of persons in each subsector [55].
Table 4 shows the resulting costs for the events in-
cluded in the model. Vaccination costs included those
corresponding to unit dose cost, average number of
doses, coverage rates, supplies and human resources.
Cost of 20 US$ per dose was used, assuming 10% losses
from waste and 1 US$ cost of administration according
to Constenla et al. [56].
Indirect costs were estimated based on loss of product-
ivity due to premature mortality from pneumococcal re-
lated diseases and costs incurred by family members
caring for sick children. To assess the former, current net
value of expected future earnings according to age at time
of death was estimated (accumulating at a yearly discount
rate of 3.5%); and for the latter, indirect costs were calcu-
lated based on human capital approach for one parent
during the acute event (in which case no discount applies
given that losses fall within the year of analysis) based on
mean wage salaries for each country [55,57-61].
Utilities
Normative utilities and disutilities values used in the model
were obtained from international sources due to the lack of
local data (see Table 5 for values used and references) and
then used to estimate population Quality-Adjusted Life-
Years (QALYs) loss. Losses in future utilities due to prema-
ture death or long term sequelae associated to events
occurring during the study year were assigned to the
present year at an annual discount rate of 3.5% in order to
estimate the net present value. Life expectancy was esti-
mated using normative utilities according to age [62].
Cost-effectiveness
Comparison of health and economic results for PHiD-
CV vaccination compared to no vaccination, allowed us
to determine differences in health benefits and costs at-
tributable to vaccination. Based on these results, and in
the case where vaccination was more costly as well as
more effective, incremental cost-effectiveness ratio
(ICER) per QALY saved and Life Year gained was esti-
mated, representing additional costs per year of life
gained adjusted for quality.
The main analysis was performed from a payer’s per-
spective, in which only direct costs were considered. For
this analysis, we used as a decision rule the Commission
on Macroeconomics and Health recommendations,
which define as very cost effective those interventions
costing less than one time the Gross Domestic Product
Table 4 Cost per event
Disease Outcome Argentina Brazil Colombia Chile Mexico Peru
Children Adults Children Adults Children Adults Children Adults Children Adults Children Adults
Average cost per acute
episode
Meningitis - hospitalized $2,166 $8,959 $548 $548 $1,407 $1,251 $2,308 $2,432 $15,484 $11,767 $506 $489
Bacteremia - hospitalized $1,002 $2,309 $417 $417 $1,090 $1,081 $578 $1,680 $6,444 $6,623 $253 $390
Pneumonia - hospitalized $1,357 $1,930 $401 $401 $529 $669 $671 $864 $4,437 $6,828 $198 $303
Pneumonia - ambulatory $127 $134 $32 $33 $52 $44 $62 $72 $427 $462 $31 $48
AOM hospitalized
myringotomy
$57 $97 $214 $214 $56 $40 $32 $50 $476 $272 $25 $27
AOM GP† consultations $68 $81 $24 $12 $31 $27 $35 $33 $343 $231 $20 $19
Annual cost for long-term
sequelae
Meningitis sequelae‡ $215 $102 $430 $543 $400 $112 $217 $59 $2,694 $856 $312 $83
Hearing loss 1st year $526 $474 $220 $243 $212 $193 $151 $193 $254 $378 $18 $78
Hearing loss long term follow
up
$152 $101 $34 $57 $92 $74 $140 $182 $203 $327 $18 $78
All costs are expressed in U$S Dollars. In Brazil, Colombia, Chile and México 2008 local costs were converted to US$ and in Argentina and Perú 2009 local costs
were converted to US$ exchange rates are provided in methods.
†GP, General practitioner.
‡except hearing loss.
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(DALY) averted, and as cost-effective those interven-
tions costing less than three times the GDP per capita
for each DALY averted. These thresholds are adhered
to by the WHO [67]. For our main analysis, we consid-
ered a cost-effectiveness threshold of less than three
times 2008 GDP per capita for Brazil R$ 45,781.53
Reais [68]; Chile $15,894,820.09 Chilean Pesos [68];
Colombia $ 29,790,816.26 Colombian Pesos [68] and
Mexico $ 341,576.84 Mexican Pesos [68]. The thresh-
old was based on 2009 GDP per capita $ 40,107.46
Nuevos Soles for Peru [68], and on 2009 GDP per
capita $ 86,425.31 Argentine Pesos for Argentina [68].Table 5 Yearly disutilities according to condition
Disutility value




AOM with myringotomy 0.005
Pneumococcal meningitis 0.023
Pneumococcal bacteremia 0.008
Long term disutilities associated with sequelae‡
Hearing loss due to AOM 0.090
Neurologic sequelae due to meningitis 0.400
Hearing loss due to meningitis 0.200
AOM, Acute Otitis Media.
†Applied to current year without discount.
‡Applied to current and subsequent years with discount.3xGDPs are expressed in US$ Dollars with the following
rates [68], for Argentina we used 2009 GDP per capita ($ =
Argentinean pesos) 1US$ = 3.87 2009 Argentina pesos, for
Brazil we used 2008 GDP per capita ($ = Reais) 1US$ = 1.84
2008 Reais, for Colombia we used 2008 GDP ($ =Colom-
bian pesos) 1US$ = 1,990 2008 Colombian pesos, for
Mexico we used 2008 GDP ($ =Mexican pesos) 1US$ =
11.16 2008 mexican pesos and for Peru we used 2009 GDP
($ =Nuevo soles) 1US$ = 3.05 2009 Nuevos soles. Also
cost-effectiveness ratios are reported in International Dol-
lars with the following rates, for Argentina we used 1 I$ = 2
Argentine pesos, for Brazil we used 1 I$ = 1.6 Reais, for
Chile we used 1 I$ = 376.1 Chilean pesos, for Colombia weSource
Assumed the same as for hospitalized bacteremia [63]
[63]
[64]
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$ = 8.1 Mexican pesos and for Peru we used 1 I$ = 1.5
Nuevos soles [68].
Sensitivity analysis
We performed one-way sensitivity analyses to explore the
impact of different parameters included in the model on
study results (comparing PHiD-CV vaccination strategy
against non-vaccination). Each parameter was varied be-
tween a range of values up and down from the base case
value. For each change, the ICER was re-estimated and
compared to the selected cost-effectiveness threshold. Re-
sults were considered robust when ICER variations were
not sufficient to modify interpretation of cost-effectiveness
of pneumococcal immunization. Table 6 shows theTable 6 Parameters included in sensitivity analysis comparing
Variable
Pneumonia – Incidence





Meningitis – Case fatality rate
Meningitis – Risk of sequelae
Bacteremia – Incidence
Bacteremia – Case fatality rate
ID - Etiology (Sp serotype distribution)
ID - Etiology (Sp in ≥10 years)
Effectiveness in reducing hospitalizations for pneumonia
Effectiveness in reducing ambulatory pneumonia
Efficacy in preventing AOM according to type of pathogen
(SpC, SpNC y HiNT)
Efficacy in preventing ID Base
Costs of administration and vaccine wastage*
Direct cost of treatment of acute events
Annual cost of long term treatment of sequelae
Disutilities associated with AOM (with and without myringotomy)
†Disutilities associated with acute diseases except AOM†
Disutilities associated with chronic conditions (sequelae)‡
ID, Invasive Disease; NTHi, Non typable Haemophilus influenzae: 95% CI: 95% confid
SpC, Streptococcus pneumoniae serotypes covered by vaccine; SpNC Streptococcus
†Per episode.
‡Per year.parameters included, the base case values and the parame-
ters ranges used in the sensitivity analyses.Results
The projected health outcomes without routine immu-
nization with PHiD-CV are shown in Table 7. Table 8
summarizes the same results but with PHiD-CV vaccin-
ation. All the results and estimations are from birth till
10 years old. The number of cases prevented in the
current year is provided for each country. The number
of deaths avoided and the total number of life years and
QALYs gained are also shown. Vaccination with PHiD-
CV caused an important reduction in number of disease
events for all health outcomes.PHiD-CV vaccination strategy against non- vaccination
Base case Range of sensitivity analysis
Age-specific data -/+20% for hospitalizations
-/+50% for ambulatory cases
Age-specific data -/+20%
Age-specific data -/+20% for myringotomies
-/+50% for total cases
Country-specific data -/+20% for Sp cases
-/+40% for NTHi cases










57.6% for SpC 95% CI
-33% for SpNC
35.3% for NTHi
d on efficacy by serotype for PCV-7 95%CI for each serotype
1 dollar with 10% wastage -/+20%
Disease-specific data -/+20%
Data specific for each condition -/+20%
Data specific for each condition 95% CI
Data specific for each condition 95% CI
Data specific for each condition 95% CI
ence interval; AOM, Acute Otitis Media; Sp, Streptococcus pneumoniae;
pneumoniae serotypes not covered by vaccine.
Table 7 Health outcomes and costs without vaccination*
Health outcomes
(number of cases)
Argentina Brazil Chile Colombia Mexico Peru
Pneumonia hospitalizations 19 435 438 803 36 761 78 137 36 925 40 710
Ambulatory pneumonia 86 086 1 487 153 207 167 148 821 108 124 43 833
Total pneumonia 105 521 1 925 956 243 928 226 958 145 049 84 543
Myringotomies 7088 36 059 5229 28 769 25 516 8072
AOM sequelae 16 005 12 490 29 490 22 448 13 395 24 362
Total AOM 422 134 1 834 559 186 538 567 084 645 551 339 758
Pneumococcal meningitis
sequelae
29 666 65.5 248 36 28
Total pneumococcal meningitis 153 1913 191.9 511 166 194
Pneumococcal bacteremia 753 7927 237 989 2702 528
Health outcomes (deaths)
Pneumonia (% from total) 449 (89.26%) 1843 (46.32%) 103 (75.18%) 1234 (88.08%) 1575 (67.34%) 1271 (93.39%)
Pneumococcal meningitis
(% from total)
25 (4.97%) 552 (13.87%) 21.4 (15.62%) 69 (4.93%) 53 (2.27%) 10 (0.73%)
Pneumococcal bacteremia
(% from total)
29 (5.77%) 1584 (39.81%) 13 (9.49%) 97 (6.92%) 711 (30.40%) 80 (5.88%)
Total deaths 503 3979 137 1401 2339 1361
Life-years lost due to
premature death
Pneumonia (% from total) 11 955 (89.32%) 47 835 (46.38%) 2767 (74.82%) 32 442 (88.10%) 41 797 (67.34%) 33 310 (93.37%)
Pneumococcal meningitis
(% from total)
656 (4.90%) 14 336 (13.90%) 576 (15.58%) 1822 (4.95%) 1400 (2.26%) 271 (0.76%)
Pneumococcal bacteremia
(% from total)
775 (5.79%) 40 974 (39.73%) 355 (9.60%) 2560 (6.95%) 18 869 (30.40%) 2096 (5.87%)
Total life- years lost due to
premature death
13 385 103 144 3698 36 823 62 066 35 677
QALYs lost
Pneumonia (% from total) 11 319 (21.19%) 54 930 (36.80%) 3979 (5.10%) 30 423 (32.92%) 38 200 (41.48%) 30 291 (32.90%)
AOM (% from total) 40 537 (75.80%) 38 632 (25.88%) 72 612 (93.12%) 56 304 (60.92%) 35 453 (38.50%) 59 385 (64.50%)
Pneumococcal meningitis
(% from total)
857 (1.60%) 19 050 (12.76%) 1067 (1.37%) 3400 (3.68%) 1583 (1.72%) 525 (0.57%)
Pneumococcal bacteremia
(% from total)
697 (1.30%) 36 656 (24.56%) 318 (0.41%) 2291 (2.48%) 16 853 (18.30%) 1874 (2.04%)
Total QALYs lost 53 410 149 267 77 976 92 418 92 089 92 075
Direct costs
Pneumonia (% from total) $ 37 285 729
(28.04%)
$ 223 194 337
(75.27%)
$ 37 536 647
(23.94%)
$ 48 992 398
(38.69%)
$ 209 948 462
(39.02%)
$ 9 452 263
(33.30%)
AOM (% from total) $ 94 445 835
(71.03%)
$ 62 909 086
(21.22%)
$ 118 366 250
(75.49%)
$ 74 526 550
(58.85%)
$ 306 229 730
(56.91%)






$ 7 110 442
(2.40%)
$ 766 387 (0.49%) $ 2 036 356
(1.61%)








$ 3 307 190
(1.12%)
$ 137 010 (0.09%) $ 1 077 341
(0.85%)




Total direct costs $132 971 513 $296 521 055 $156 806 295 $126 632 644 $ 538 098 849 $ 28 385 203
Indirect costs
Pneumonia (% from total) $ 26 513 765
(26.15%)
$ 205 729 961
(46.78%)
$ 15 989 127
(10.53%)
$ 57 757 864
(39.05%)
$ 55 732 299
(38.26%)
$ 49 187 200
(36.56%)
AOM (% from total) $ 71 941 758
(70.95%)




$ 82 516 905
(55.78%)
$ 43 309 768
(29.73%)
$ 79 622 249
(59.18%)
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Table 7 Health outcomes and costs without vaccination* (Continued)
Pneumococcal meningitis
(% from total)
$ 1 473 497
(1.45%)
$ 78 064 982
(17.75%)
$ 681 723 (0.45%) $ 3 823 700
(2.58%)
$ 23 319 138
(16.01%)




$ 1 473 497
(1.45%)
$ 78 064 982
(17.75%)
$ 681 723 (0.45%) $ 3 823 700
(2.58%)
$ 23 319 138
(16.01%)
$ 2 864 722
(2.13%)
Total indirect costs $101 402 517 $439 783 244 $151 866 092 $147 922 168 $145 680 345 $134 538 893
*Analysis is from birth till 10 years of age, discount rate 3.5. All costs are expressed in U$S Dollars. In Brazil, Colombia, Chile and México 2008 local costs were
converted to US$ and in Argentina and Perú 2009 local costs were converted to US$ exchange rates are provided in methods.
% from total refers to the percentage of cases attributable to the condition from the total of cases or costs.
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observed in pneumococcal meningitis (range 26.56% for
Peru up to 47.44% for Colombia), neurologic sequelae after
meningitis (range between 37.80% for Peru and 65.46% for
Brazil) and bacteremia (range 42.34% for Argentina up to
49.34% for Colombia). Otherwise in absolute number of
cases the largest effect was observed in pneumonia and
AOM. Also, the model showed a significant proportion of
pneumococcal related deaths were averted annually after
PHiD-CV introduction (range between 17.65% for Peru
and 33.43% for Brazil). Overall, the health benefits achieved
with PHiD-CV vaccination resulted in a lower QALY loss
(range from 14.73% lower for Peru up to 26.28% for Brazil).
The differences between countries could be explained due
to differences in specific etiology and serotype distribution
estimations. There were no much differences on pneumo-
nia effect because its etiology was not considered in the
model but differences were shown in otitis, meningitis and
bacteremia based on considering its specific etiology.
In addition to the health benefits, the introduction of
PHiD-CV averted costs when compared with non-
vaccination. Reduction in total direct costs varied between
13% for Peru and 17% for Argentina, representing a range
of cost offsets between 3.69 million dollars (Peru) and 22.7
millions (Argentina). Economic benefits for PHiD-CV
were in general greatest for AOM, this may be explained
because AOM was the major cost driver in the base case
scenario. Brazil was the only country were the major cost
driver was pneumonia. These differences could be attrib-
uted to differences in incidence and events costs estima-
tions between countries.
At a cost of 20 US$ for vaccine dose for all countries,
compared to non-vaccination, cost-effectiveness analysis
demonstrated significant health benefits in favor of
10-valent pneumococcal vaccination implementation,
with ICER values between being cost saving in Chile ICER
-230.13 US$ per QALY gained (where the vaccination
strategy was less costly than the no vaccination one) to
7,088.64 US$ per QALY gained in Brazil (Table 9). The
cost saving ICER in Chile could be explained due to a
greater estimation of disease burden in comparison to
other countries in pneumonia and AOM cases being the
intervention relatively more cost effective. Chilean pneu-
monia hospitalizations were obtained from national healthstatistics and AOM cases from a local Chilean study,
maybe these higher values can be explained due to a more
developed statistics system or in the case of AOM due to
a more detection of cases because of active surveillance in
the context of the study. This greater pneumonia and
AOM disease burden estimation associated with the im-
pact shown in the sensitivity analysis of the pneumonia
hospitalization reduction parameter could lead to a cost
saving ICER estimation in Chile. The results of the cost-
effectiveness analysis under different scenarios (consider-
ing herd protection and indirect costs) are also presented
(Table 10). As shown in the table, the incorporation of in-
direct costs had a greater influence than that of herd im-
munity (in the assumed scenario). Table 9 contains main
results expressed in International Dollars (I$) [68] in com-
parison with 3 GDP threshold.
Sensitivity analyses performed on the ICER of PHiD-CV
vaccination compared with non-vaccination is shown in
Table 11. The most influential variables are listed. In gen-
eral, variables related to AOM and pneumonia had the
greatest impact on ICER in all countries except Brazil,
where IPD related variables affected ICER most (these can
be explained due to the high estimation of bacteremia in
Brazil in comparison with others countries). Nonetheless,
changes were never large enough to surpass 3 times GDP
cost-effectiveness threshold. Even considering 1 GDP,
most countries estimations were below this threshold indi-
cating that cost effectiveness estimations were robust.
Conclusions
The initial economic evaluations of pneumococcal con-
jugated vaccines provided conflicting results. A review of
studies in Europe and the US by De Graeve et al. [69]
concluded that economic attractiveness of universal
PCV vaccination strategies were dependent on both vac-
cine cost and willingness of decision makers to adopt a
societal perspective. Similarly, Beutels et al. published a
review of 15 economic analyses of heptavalent pneumo-
coccal conjugate vaccine [70] and found that the cost of
the vaccination program and the impact of herd immun-
ity were highly influential parameters for cost effective-
ness. Those studies considered high vaccine prices per
dose and do not include AOM in the analysis. More re-
cent studies in Latin America estimated PCV7 to be cost
Table 8 Health outcomes and costs after PHiD-CV vaccination: comparative analysis vs non-vaccination*





2851 (14.67) 69 415 (15.82) 5709 (15.53) 12 257 (15.69) 6112 (16.55) 6391 (15.70)
Ambulatory pneumonia - N(%) 1292 (1.50) 30 443 (2.05) 4198 (2.03) 2270(1.53) 2887 (2.67) 689 (1.57)
Total pneumonia - N(%) 4143 (3.93) 99 859 (5.18) 9907 (4.06) 14 527 (6.40) 8999 (6.20) 7080 (8.37)
Myringotomies - N(%) 3708 (52.32) 12 532 (34.75) 2461 (47.06) 11 031 (38.34) 9395 (36.82) 2945 (36.48)
AOM sequelae - N(%) 3272 (20.45) 1643 (13.16) 5101 (17.30) 3085 (13.74) 2075 (15.49) 3209 (13.17)
Total AOM - N(%) 67 519 (15.99) 188 353 (10.27) 29180 (15.64) 55 098 (9.72) 75 534 (11.70) 33 323 (9.81)
Pneumococcal meningitis
sequelae - N(%)
16 (56.65) 436 (65.46) 32 (48.96) 147 (59.36) 23 (64.87) 11 (37.80)
Pneumococcal meningitis - N(%) 72 (47.32) 876 (45.78) 78 (40.54) 243 (47.44) 70 (42.32) 52 (26.56)
Pneumococcal
bacteremia - N(%)
319 (42.34) 3812 (48.08) 107 (45.07) 488 (49.34) 1169 (43.26) 232 (43.89)
Health outcomes (deaths
averted)
Pneumonoia - N(%) 69 (15.28) 284 (15.40) 16 (15.60) 192 (15.58) 251 (15.92) 199 (15.64)
Pneumococcal
meningitis - N(%)
12 (47.32) 282 (51.06 9 (40.85) 36 (52.07) 23 (43.52) 41 (39.29)
Pneumococcal
bacteremia - N(%)
14 (48.45) 764 (48.27) 6 (44.09) 50 (51.68) 306 (43.08) 37 (46.78)
Total deaths averted - N(%) 94 (18.77) 1330 (33.43) 31 (22.27) 279 (19.89) 580 (24.80) 240 (17.65)
Life- years gained
Pneumonia - N(%) 1829 (15.30) 7379 (15.43) 432 (15.60) 5060 (15.60) 6660 (15.93) 5216 (15.66)
Pneumococcal
meningitis - N(%)
310 (47.35) 7335 (51.17) 236 (40.95) 950 (52.13) 610 (43.55) 107 (39.39)
Pneumococcal
bacteremia - N(%)
376 (48.50) 19 791 (48.30) 157 (44.11) 1324 (51.73) 8132 (43.10) 982 (46.84)
Total life- years gained - N(%) 2515 (18.79) 34 505 (33.45) 824 (22.28) 7334 (19.92) 15 402 (24.81) 6305 (17.67)
QALYs gained
Pneumonia - N(%) 1661 (14.67) 7315 (13.32) 455 (11.43) 4623 (15.20) 6004 (15.72) 4708 (15.54)
AOM - N(%) 8215 (20.27) 4866 (12.60) 12 560 (17.30) 7671 (13.62) 5405 (15.25) 7789 (13.12)
Pneumococcal meningitis - N(%) 406 (47.42) 9336 (49.01) 449 (42.05) 1725 (50.72) 684 (43.23) 190 (36.13)
Pneumococcal bacteremia - N(%) 338 (48.45) 17 706 (48.30) 140 (44.11) 1185 (51.73) 7263 (43.10) 878 (46.83)
Total QALYs gained - N(%) 10658 (19.95) 39 223 (26.28) 13 604 (17.45) 15 204 (16.45) 19 357 (21.02) 13 565 (14.73)
Direct costs (savings)
Pneumonia - N(%) $ 4 033 877 (11) $ 28 797 257 (13) $ 4 092 194 (11) $ 6 596 723 (13) $ 28 348 389 (14) $ 1 289 409 (14)
AOM - N(%) $ 18 167 102 (19) $ 8 683 587 (14) $ 20 426 178 (17) $ 9 909 792 (13) $ 41 651 823 (14) $ 2 252 166 (12)
Pneumococcal meningitis - N(%) $ 229 857 (47) $ 3 187 488 (45) $ 319 239 (42) $ 986 297 (48) $ 1 902 325 (42) $ 93 682 (31)
Pneumococcal
bacteremia - N(%)
$ 319 575 (42) $ 1 590 258 (48) $ 61 749 (45) $ 531 578 (49) $ 7 532 168 (43) $ 58 707 (44)
Total direct costs saving - N(%) $ 22 750 411 (17) $ 42 258 590 (14) $ 24 899 359 (16) $ 18 024 390 (14) $ 79 434 704 (15) $ 3 693 964 (13)
Indirect costs (savings)
Pneumonia - N(%) $ 3 522 333 (13) $ 22 241 122 (11) $ 1 400 094 (9) $ 8 252 215 (14) $ 8 557 686 (15) $ 7 451 232 (15)
AOM - N(%) $ 14 517 543 (20) $ 9 740 639 (13) $ 23 286 312 (17) $ 11 218 127 (14) $ 6 612 602 (15) $ 10 446 078 (13)
Pneumococcal meningitis- N(%) $ 774 859 (47) $ 19 723 810 (48) $ 905 497 (41) $ 2 707 444 (50) $ 925 147 (43) $ 287 348 (35)
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Table 8 Health outcomes and costs after PHiD-CV vaccination: comparative analysis vs non-vaccination* (Continued)
Pneumococcal
bacteremia - N(%)
$ 703 551 (48) $ 37 630 952 (48) $ 299 735 (44) $ 1 966 433 (51) $ 10 054 366 (43) $ 1 340 000 (47)
Total indirect costs - N(%) $ 19 518 286 (19) $ 89 336 523 (22) $ 25 891 638 (17) $ 24 144 218 (16) $ 26 149 800 (21) $ 19 524 658 (15)
Cost of vaccination
Cost of vaccination $ 58 299 995 $ 320 297 067 $ 21 768 674 $ 79 164 045 $ 168 367 142 $ 44 052 353
*Analysis is from birth till 10 years of age, discount rate 3.5. All costs are expressed in U$S Dollars. In Brazil, Colombia, Chile and México 2008 local costs were
converted to US$ and in Argentina and Perú 2009 local costs were converted to US$ exchange rates are provided in methods.
% from total refers to the percentage of cases attributable to the condition from the total of cases or costs.
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and Uruguay [56] considering AOM in their evaluated
outcomes.
The results of the present analysis show that the intro-
duction of the 10-valent pneumococcal non-typable Hae-
mophilus influenzae protein D-conjugate vaccine into
routine infant immunization programs in Latin American
countries can significantly reduce the health and economic
burden of pneumococcal disease. Vaccination with PHiD-
CV in a 3 + 1 schedule at 20 US$ per dose proved to be a
cost effective intervention, according to international cri-
teria, in all countries analyzed. This result was achieved
mainly due to the high disease burden averted (high
pneumococcal serotypes coverage and protection against
NTHi associated AOM) and the vaccine cost estimated in
the base case scenario. In addition, the results obtained in
this analysis proved to be robust, and the cost effectiveness
of the vaccine was below the 3 GDP per capita threshold
based on WHO standards [67], over a broad range of
values for variables included in sensitivity analysis. In
Brazil alone, the results were slightly above 1 GDP per
capita while in the other countries the results were below
this conservative threshold. The project lasted for many
years and the most difficult challenge was to obtain model
parameters prioritizing the use of local epidemiological
data and costs.
Economic analyses in the Latin American region are
often hindered by lack of epidemiological data. We
conducted an extensive search of the literature to iden-
tify the best available data, validated by local experts for
this study. Data reliability is crucial for accurate deter-
mination of outcomes. As an example, sources for AOM
incidence rates were very scarce in our region and as
mentioned, they have a great impact on study results.
Surveillance studies usually overestimate AOMTable 9 Cost effectiveness analysis (International Dollars)
Argentina Brazil
3xGDP per capita threshold $ 44,116.90 $ 29,327.99
ICER - QALYs gained $ 6,629.23 $ 8,354.35
ICER - Life years gained $ 27,995.01 $ 9,496.72
3xGDPs are expressed in 2009 International Dollars with the following rates, for Arg
Chile we used 1 I$ = 376.1 Chilean pesos, for Colombia we used 1 I$ = 1,228 Colomb
1 I$ = 1.5 Nuevos soles.incidence rates while case report studies tend to under-
estimate them. A study of AOM in Boston children,
reported an annual incidence rate of 120,000 per
100,000 children under 1 year of age [72]. Conversely,
Arévalo et al. found an incidence rate of 1,260 per
100,000 children aged < 1 year and 1,083 per 100,000
children aged 1 to 4 years in spontaneously reported
cases of AOM in Mexico [73]. Melegaro et al. have
reported an annual AOM consultation rate of 24,000 per
100,000 children aged < 4 years [74] in the United King-
dom. Overall, we have used conservative AOM inci-
dence rates based on three different local sources. In
addition, some of the epidemiological data used were
obtained from national health statistics and in absence
of information, we based our analysis on expert opinion
and Delphi panels. On the other hand, utility and disutil-
ity values were obtained from international sources due
to lack of local data. Regarding model assumptions, as
etiology of pneumonia cases is not fully understood, we
used a vaccine effectiveness estimate for all-cause pneu-
monia from a US clinical trial of PCV-7 for all countries.
As explained, the variations observed in the percentage
of cases and deaths averted between countries are based
on the different specific etiology and serotype distri-
bution estimations assumed for each country. We
conducted an extensive one way sensitivity analysis and
were able to conclude that our results are quite robust,
although a study limitation that may underestimate deci-
sion uncertainty is that a probabilistic sensitivity analysis
was not included [75].
Some limitations of this study are that we did not in-
clude a comparison against other pneumococcal vaccines
(at the time of the analysis the 13-valent vaccine was re-
cently introduced in the market) and that we analyzed
only one vaccination scheme (comparison informationChile Colombia Mexico Peru
$ 42,261.21 $ 24,260.33 $ 42,347.63 $ 26,420.95
$ -320.44 $ 6,518.50 $ 6,358.39 $ 5,986.93
$ -5,290.74 $ 13,513.13 $ 7,991.33 $ 12,881.14
entina we used 1 I$ = 2 Argentine pesos, for Brazil we used 1 I$ = 1.6 Reais, for
ian pesos, for Mexico we used 1 I$ = 8.1 Mexican pesos and for Peru we used
Table 10 Cost effectiveness analysis (US Dollars)
Argentina Brazil Chile Colombia Mexico Peru
Main analysis
ICER - QALYs gained $ 3,347.53 $ 7,088.64 $ -230.13 $ 4,021.37 $ 4,594.33 $ 2,975.23
ICER - Life years gained $ 14,136.50 $ 8,057.94 $ -3,799.67 $ 8,336.48 $ 5,774.23 $ 6,401.33
3xGDP per capita threshold $ 22,277 $ 24,884 $ 27,021 $ 14,966 $ 30,598 $ 13,129
Secondary analysis
ICER - QALYs gained
Base case + indirect costs $ 1,509.59 $ 4,810.99 $ -2,133.38 $ 2,433.32 $ 3,243.41 $ 1,535.87
Base case + herd immunity $ 3,295.13 $ 6,293.05 -235.11 $ 3,885.80 $ 4,144.01 $ 2,920.73
Base case + indirect effect + herd immunity $ 1,454.51 $ 4,024.69 -2,141.37 $ 2,295.77 $ 2,790.71 $ 1,478.95
ICER - Life years gained
Base case + indirect costs $ 6,374.94 $ 5,468.84 $ -35,223.99 $ 5,044.38 $ 4,076.37 $ 3,304.48
Base case + herd immunity $ 13,439.35 $ 7,092.43 -3,511.26 $ 7,928.28 $ 5,059.29 $ 6,186.27
Base case + indirect effect + herd immunity $ 5,932.31 $ 4,535.93 -31,980.90 $ 4,684.11 $ 3,307.09 $ 3,132.50
ICER, Incremental cost-effectiveness ratio QALYs, Quality-adjusted life-years HP: Herd protection IC, Indirect costs.
All costs are expressed in US$ Dollars. In Brazil, Colombia, Chile and México 2008 local costs converted to US$ and in Argentina and Peru 2009 local costs were
converted to US$ exchange rates are provided in methods.
Table 11 Sensitivity analysis
Country Parameter ICER range# 3xGDP $*
Argentina Efficacy in preventing NTHI AOM (CI 95%) $6,689.27 $3,753.22 $ 22,277
AOM - Etiology (Sp -/+20%, NTHI -/+ 40%) $5,959.08 $3,724.97
AOM - Etiology (Sp -/+ 20%) $5,701.40 $3,886.36
AOM -Disutility for hearing loss (CI 95%) $5,622.58 $3,982.36
Efficacy in preventing Sp AOM (CI 95%) $5,501.06 $3,989.9
Brazil Bacteremia-Incidence (+/-50%) $10,397.98 $6,021.45 $ 24,884
Efficacy in preventing hospitalization for pneumonia (CI 95%) $9,393.87 $6,311.59
Meningitis-Incidence (-/+50%) $8,758.52 $6,667.62
Vaccine efficacy ramp-up (-/+ 20%, CI 95%) $8,526.38 $6,920.00
Efficacy in preventing invasive disease (CI 95%) $8,035.13 $7,261.63
Colombia Efficacy in preventing hospitalization for pneumonia (CI 95%) $5,208.56 $3,195.50 $ 14,966
Efficacy in preventing NTHI AOM (CI 95%) $5,039.76 $3,502.43
AOM - Etiology (Sp -/+20%, NTHI -/+ 40%) $4,864.28 $3,381.48
AOM - Etiology (Sp -/+ 20%) $4,775.73 $3,433.84
AOM -Disutility for hearing loss (CI 95%) $4,781.43 $3,469.80
Mexico Efficacy in preventing NTHI AOM (CI 95%) $6,909.40 $3,408.91 $ 30,598
Efficacy in preventing hospitalization for pneumonia (CI 95%) $6,638.91 $3,181.98
AOM - Etiology (Sp -/+20%, NTHI -/+ 40%) $5,830.11 $3,564.65
Bacteremia-Incidence (+/-50%) $5,894.39 $3,704.39
AOM - Incidence (Myringotomies -/+ 20%, Total Cases -/+ 50%) $5,364.50 $3,839.01
Peru Efficacy in preventing hospitalization for pneumonia (CI 95%) $3,813.47 $2,422.55 $ 13,129
AOM -Disutility for hearing loss (CI 95%) $3,649.05 $2,511.47
Efficacy in preventing NTHI AOM (CI 95%) $3,706.67 $2,617.21
AOM - Etiology (Sp -/+20%, NTHI -/+ 40%) $3,577.81 $2,535.13
AOM - Etiology (Sp -/+ 20%) $3,513.24 $2,570.60
* 3GDP per capita threshold: 3 times Gross Domestic Product per capita. Values are expressed in U$S Dollars, conversion rates are provided in methods.
#ICER expressed per QALY gained.
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http://www.resource-allocation.com/content/11/1/21against different vaccination schemes was not available).
Assuming that a 2 + 1 scheme would be close in efficacy
to a 3 + 1 but at a lower cost, the results of our analysis
are conservative. In addition this was an ambitious project
that lasted many years and we are now presenting the first
results in this manuscript. Publications with further ana-
lysis on different scenarios (schedules) per country and
comparison between vaccines are in progress. A few com-
parative studies [76,77] on the cost effectiveness of
pneumococcal conjugated vaccines were published re-
cently, and their results are encouraging.
Although the current PAHO revolving fund vaccine
price per dose is around 14 USD, we used 20 USD per
dose in our analysis to assume a conservative scenario.
In our study, the vaccine shows to be highly cost effect-
ive even in this scenario. In Latin America, once a vac-
cine is included in the PAHO revolving fund there is no
price negotiation.
In this study we are presenting a cost effectiveness
evaluation of the incorporation of the 10-valent pneumo-
coccal conjugate vaccine for several Latin American coun-
tries. In a context where decisions are not always driven
by evidence, our study provides a detailed description of
many aspects of the disease burden estimation needed to
carry out an economic evaluation, and shows that the
adoption of the vaccine has the potential to become a valid
strategy to reduce disease burden and infant mortality
while optimizing the use of available and scarce resources
in these developing countries.
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